CZ25462U1 - Probiotic compositing for intranasal application - Google Patents

Description

Technical field

The technical solution concerns a probiotic preparation for intranasal application.

Background Art

Lactobacilli and bifidobacteria are among the microorganisms used in dairy technology in the production of cheeses, cottage cheese and fermented dairy products. These microorganisms, according to a number of serious research studies, also have significant effects on human health. The application of probiotics in the prevention and treatment of dysmicrobia has been studied for a long time and the results indicate a good response of the human organism. Especially important are the immunomodulatory properties of lactobacilli and bifidobacteria that can contribute to the prevention and treatment of disease by initiating a proper immune response.

The most common application of probiotic microorganisms to take these microorganisms into the human body is by way of a well-prepared dairy product where the high intake of beneficial microflora is guaranteed. Additional applications are possible through nutritional supplements. Through this, the probiotic microflora will be delivered to the human body even to those who cannot or do not want to receive dairy products. This application also provides sufficient numbers of microorganisms per tablet or capsule.

The consumption of lactic acid bacteria and the uptake of these microorganisms, due to their effect on human health, is only suitable in the case of verified certain properties of these microorganisms. In particular, it is the good vitality of microorganisms when passing through the digestive tract, their resistance to low pH in the stomach and bile as they pass through the proximal part of the small intestine.

Probiotics have a wide range of important properties and affect human health if they reach the gastrointestinal tract at a sufficient density and if they have the ability to remain in the digestive tract for some time. Inflammations of the upper respiratory tract and their complications in the form of inflammation of the middle ear and nasal sinuses are frequent illnesses in the winter months, which bring many problems to children and adults.

Probiotics are used for the prevention or supportive treatment of these diseases because of their immunomodulatory properties and are applied in the manner described above, which reaches the mucous membranes of the oral cavity, pharynx, esophagus, stomach and intestines. In the area of the nasopharynx, or up to the nasal mucosa, they get rather rarely - when the palate is disturbed. For the viral attack of the organism, the most exposed areas are the mucous membranes of the nose and the nasopharynx, but the direct antibacterial action of the lactobacilli, which can be demonstrated by culture tests, cannot be applied.

The essence of the technical solution

The above-mentioned drawbacks are eliminated by the probiotic intranasal formulation of the present invention, which comprises Lbe strains. acidophilus and Lbe. Helveticus in a balanced ratio of 10 ⁶ to 10 ⁹ in one gram of product, and further contains other Lactobacillus and bifidobacteria species in a density of 10 to 10 in one gram of product.

The probiotic preparation for intranasal administration according to the present invention has the advantage that it is a preparation without secondary effects on other organs, has an acceptable form for application which is carried out directly on the mucosa of the nose and nasopharynx. In this way, the probiotic enters the mucosa directly, rinses the mucosa and can settle the application site.

The bacteria of the genus Lactobacillus have a beneficial effect by preparing undesirable bacteria for living space and preventing their use based on competition for nutrition.

CZ 25462 Ul

Examples of technical solutions

1. The preparation for intranasal administration contains the strain Lbe. acidophilus at 10 ⁷ and Lbe strain. helveticus at a density of 10 ⁷ per gram of product.

2. The preparation for intranasal administration contains the strain Lbe. acidophilus at 10 ⁷ and Lbe strain.

helveticus at a density of 10 ⁷ and further contains the Lbe strain. rhamnosus at 10 ⁶ and Bifidobacterium sp. at a density of 10 ⁶ per gram of product.

3. The preparation for intranasal administration contains the Lbe strain. acidophilus at 10 ⁸ and Lbe strain. helveticus at a density of 10 ⁸ and further contains the Lbe strain. casei in density 10 ⁷ , Lbe. plantarum at 10 ⁷ and Bifidobacterium bifidum at 10 ⁷ per gram of product.

First, a mixture of probiotics composed of strains of Lactobacillus acidophilus and Lactobacillus helveticus is prepared in a balanced ratio. For ease of application, the strains are frozen or lyophilized and dosed into suitable packages.

Prior to application, the composition is subsequently transferred to an aqueous solution (1% by weight) which can be applied directly to the nasal mucosa and nasopharynx.

Experience in the application of culture at the time of the first symptoms of colds or inflammation of the upper respiratory tract was obtained. After applying the culture to the nose and mouth, holding in the mouth and then swallowing, the symptoms of the disease did not develop further. Although repeated colds, inflammation of the upper respiratory tract and inflammation of the middle ear, users have commonly suffered.

Claims (2)

PROTECTION REQUIREMENTS 20 1. A composition for intranasal administration comprising strains Lactobacillus acidophilus and Lactobacillus helveticus in a balanced ratio at a density of 10 ⁶ to 10 ⁹ per gram of product. The preparation for intranasal administration according to claim 1, characterized in that it further comprises other species of Lactobacillus and bifidobacteria in a density of 10 ⁶ to 10 ⁸ in one. 25 grams of product.